MDNews - Lower Hudson/Bronx

November 2016

Issue link: https://viewer.e-digitaledition.com/i/746097

Contents of this Issue

Navigation

Page 15 of 23

IBS IBS RESE ARCHERS A SSESSING THE ROLE THAT VENOM PL AYS IN ACTIVATING NERVE FIBERS INVOLVED IN PAIN SENSATION HAVE UNCOVERED A SURPRISING MECHANISM THAT MAY INFLUENCE IRRITABLE BOWEL SYNDROME ¥IBS¦›REL ATED PAIN. May Hold Key to Treating AN E STIMATED 10 TO 15 PERCENT of Americans live with IBS, according to the American College of Gastroenterology. A diagnosis of exclusion, the syndrome can cause lower abdominal pain, bloating and changes in bowel habits. While some patients have mild symptoms that respond to over-the-counter medica- tion, others experience signifi cant pain and distress that greatly a ect their quality of life. Brian Kirsh, MD, a gastroenterologist at Cleveland Clinic, has evaluated patients who have rated their IBS-associated pain as high as 10 on the Comparative Pain Scale. There is currently no cure for IBS, but management strategies can relieve symptoms. First-line therapies include antispasmodic medications designed to prevent abdominal-muscle contractions. In the past fi ve to 10 years, the FDA has also approved medications for constipation-predominant and diarrhea-predominant IBS. Additionally, some patients benefi t from behavioral and dietary modifi cations, as well as complementary therapies, such as hypnosis and relaxation therapy. Despite the availability of medication and other manage- ment strategies, many people — especia lly those who have post-infectious IBS or mixed-motility IBS, which presents as alternating episodes of constipation and diarrhea — continue to experience chronic abdominal pain. AN UNEXPECTED DISCOVERY The international team behind research published recently in Nature did not initia lly intend to study IBS. Rather, the researchers sought to gain further knowledge about the activity of sensory nerve fi bers that are devoted to painful stimuli. Of particular interest to the team were naturally occurring, pungent agents that are known to activate nerve fi bers involved in pain sensation. David Julius, PhD, a co-lead author of the study and Professor and Chair, Department of Physiology, University of California, San Francisco, has previously focused on the role of capsaicin and wasabi in stimulating a pain response. Studying venom was a natural evolution. "The study [was] based on the premise that creatures such as spiders have evolved over millions of years to be very successful in surviving within their environment," says Professor Stuart Brierley, PhD, a co-lead author of the study and Head of the Visceral Pain Research Group at Flinders University and the South Australian Health and Medical Research Institute in Adelaide. "Therefore, the venom they release when they bite is not just used to capture prey for food — it also needs to be used to deter predators. The best way to deter predators is to inject them with something that causes immediate pain. Thus, we screened a large panel of spider and scorpion venoms, looking for those that activated pain-sensing neurons." Researchers screened 109 spider, scorpion and centipede venoms using a cell-based assay. Once a "hit" venom — one that elicited strong activation of pain-sensing neurons — was identifi ed, the venom was fractionated into individual peptide components to identify the active molecule responsible for induc- ing pain. Venom from the tarantula species Heteroscodra maculata elicited the most robust response. Toxins found in the venom induced the pain response by acting on the Na v 1.1 voltage-gated sodium channel. "Once we identifi ed Na v 1.1, this was interesting to us because we know that sodium channels are important, as they are in all neurons for sending signals from the periphery to the central nervous system and spinal cord," Julius says. "But in all of the SPIDER VENOM IBS BY TIFFANY PARNELL SPECIAL CLINICAL SECTION: GASTROENTEROLOGY 1 6

Articles in this issue

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - November 2016